LENZ Therapeutics (LENZ) 주식 개요
는 미국에서 시력 개선을 위한 치료법 개발 및 상용화에 주력하는 상업용 제약 회사로 운영되고 있습니다. 자세히 보기
LENZ Community Fair Values
Create NarrativeSee what 34 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
LENZ Therapeutics
97.7% 저평가 내재 할인율
LENZ Therapeutics - a high risk high reward small cap biotech stock
View narrativeMO
Published 17 Sep 2025
LENZ Therapeutics, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$4.52 |
| 52주 최고가 | US$50.40 |
| 52주 최저가 | US$4.50 |
| 베타 | 1.63 |
| 1개월 변동 | -1.74% |
| 3개월 변동 | -33.23% |
| 1년 변동 | -89.07% |
| 3년 변동 | n/a |
| 5년 변동 | n/a |
| IPO 이후 변동 | -72.10% |
최근 뉴스 및 업데이트
Seeking Alpha • Sep 04
LENZ Therapeutics: Still Speculative But Priced For Disasters
Summary LENZ Therapeutics is rated a 'Strong Buy' with a fair value estimate of $21.3, reflecting ~266% upside from current levels. I model peak US Vizz sales at $375M, using a 5-pack annualized purchase rate and 30% market share, with conservative international assumptions. LENZ's speculative nature persists due to single-product risk, high SG&A, uninsured status, and rising competition; position sizing remains limited. Short-term signals are mixed, but technicals, insider buying, and potential for a short squeeze reinforce my bullish stance. Read the full article on Seeking Alpha
내러티브 업데이트 • Sep 03
LENZ: Slower Presbyopia Launch Will Eventually Set Up Future Repricing
The analyst price target for LENZ Therapeutics has shifted from $12 to $7, as analysts point to a slower than expected VIZZ launch, reduced peak sales assumptions, and a focus on cash value, while also acknowledging slightly higher projected profit margins and a lower future P/E in updated models. Analyst Commentary Recent research on LENZ Therapeutics points to a more cautious tone around the VIZZ eye drop launch, with several bearish analysts reducing price targets and reassessing execution risk on the commercial ramp.분석 기사 • Aug 14
Earnings Release: Here's Why Analysts Cut Their LENZ Therapeutics, Inc. (NASDAQ:LENZ) Price Target To US$26.83
LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) investors will be delighted, with the company turning in some strong numbers...
내러티브 업데이트 • Aug 14
LENZ: Telehealth Launch And Cash Support Will Shape Future Upside Potential
LENZ Therapeutics now carries a lower analyst price target centered around $7, down from prior expectations closer to $31. Analysts are reassessing the stock in light of slower than expected VIZZ presbyopia launch trends, reduced peak sales assumptions, and a heavier focus on cash value.분석 기사 • Jul 15
We're Hopeful That LENZ Therapeutics (NASDAQ:LENZ) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Recent updates
Seeking Alpha • Sep 04
LENZ Therapeutics: Still Speculative But Priced For Disasters
Summary LENZ Therapeutics is rated a 'Strong Buy' with a fair value estimate of $21.3, reflecting ~266% upside from current levels. I model peak US Vizz sales at $375M, using a 5-pack annualized purchase rate and 30% market share, with conservative international assumptions. LENZ's speculative nature persists due to single-product risk, high SG&A, uninsured status, and rising competition; position sizing remains limited. Short-term signals are mixed, but technicals, insider buying, and potential for a short squeeze reinforce my bullish stance. Read the full article on Seeking Alpha내러티브 업데이트 • Sep 03
LENZ: Slower Presbyopia Launch Will Eventually Set Up Future Repricing
The analyst price target for LENZ Therapeutics has shifted from $12 to $7, as analysts point to a slower than expected VIZZ launch, reduced peak sales assumptions, and a focus on cash value, while also acknowledging slightly higher projected profit margins and a lower future P/E in updated models. Analyst Commentary Recent research on LENZ Therapeutics points to a more cautious tone around the VIZZ eye drop launch, with several bearish analysts reducing price targets and reassessing execution risk on the commercial ramp.분석 기사 • Aug 14
Earnings Release: Here's Why Analysts Cut Their LENZ Therapeutics, Inc. (NASDAQ:LENZ) Price Target To US$26.83
LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) investors will be delighted, with the company turning in some strong numbers...내러티브 업데이트 • Aug 14
LENZ: Telehealth Launch And Cash Support Will Shape Future Upside Potential
LENZ Therapeutics now carries a lower analyst price target centered around $7, down from prior expectations closer to $31. Analysts are reassessing the stock in light of slower than expected VIZZ presbyopia launch trends, reduced peak sales assumptions, and a heavier focus on cash value.분석 기사 • Jul 15
We're Hopeful That LENZ Therapeutics (NASDAQ:LENZ) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...내러티브 업데이트 • Jul 10
LENZ: Telehealth Launch And Advertising Push Will Drive Future Upside Potential
Analysts have reset expectations for LENZ Therapeutics, with the consolidated fair value estimate declining from $53.71 to $32.00 as they factor in updated price targets, a slightly higher discount rate, more moderate revenue growth assumptions, a higher projected profit margin, and a lower future P/E multiple. Analyst Commentary Recent research updates on LENZ Therapeutics point to a more mixed analyst stance, with some focusing on long term upside potential and others emphasizing execution risks and valuation reset drivers.내러티브 업데이트 • Jun 26
LENZ: Presbyopia Partnership And UK Filing Will Drive Future Repricing
The analyst price target for LENZ Therapeutics has moved from $37.91 to $12.00 as analysts recalibrated their expectations, citing a mix of lower targets from firms like Citi and H.C. Wainwright, a modest upward revision from BofA, and recent rating changes. Analyst Commentary Recent analyst updates for LENZ Therapeutics show a tilt toward more cautious views, with several price targets adjusted and at least one downgrade, which together frame a more conservative stance on the stock.분석 기사 • May 16
Some LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Just Made A Major Cut To Next Year's Estimates
Today is shaping up negative for LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) shareholders, with the analysts delivering a...분석 기사 • May 14
Earnings Update: LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Reported And Analysts Are Trimming Their Forecasts
It's been a mediocre week for LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) shareholders, with the stock dropping 17% to...분석 기사 • Apr 30
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Just Trimmed Their Revenue Forecasts By 12%
Today is shaping up negative for LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) shareholders, with the analysts delivering a...분석 기사 • Mar 29
Analysts Just Slashed Their LENZ Therapeutics, Inc. (NASDAQ:LENZ) EPS Numbers
Today is shaping up negative for LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) shareholders, with the analysts delivering a...분석 기사 • Mar 27
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Are Cutting Their Estimates: Here's What You Need To Know
LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) just released its latest yearly report and things are not looking great. It was...분석 기사 • Dec 13
Here's Why We're Not At All Concerned With LENZ Therapeutics' (NASDAQ:LENZ) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...분석 기사 • Nov 08
Earnings Beat: LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) just released its third-quarter report and things are looking bullish. Results...Seeking Alpha • Mar 27
LENZ Therapeutics Stock Is Attractive Before PDUFA
Summary LENZ Therapeutics, Inc.'s LNZ100 eye drop shows promising results for presbyopia, with strong phase 3 data and potential FDA approval by August 2025. LNZ100 demonstrated superior efficacy compared to AbbVie's Vuity, with a broad patient range and rapid onset of treatment effect. Survey data indicates high interest among eye care professionals, with 82% likely to prescribe LNZ100 if approved, targeting a $3bn market. Despite competitive risks, LNZ100's potential market penetration and Lenz's strong financial position make it a cautiously attractive investment. Read the full article on Seeking Alpha분석 기사 • Jan 01
Companies Like LENZ Therapeutics (NASDAQ:LENZ) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Nov 27
LENZ Therapeutics: Time For A Pause
Summary Today, we take a look Lenz Therapeutics, which may be on the verge of approval for a 'best of breed' solution for near vision loss. The company has a solid balance sheet, is putting a sales organization in place and the compound is very likely to be approved next August. That said, the stock has more than doubled in the past six months and trading levels now exceed most analyst firm price targets. More legs to this rally or are the shares overdue for a pause? An analysis around Lenz Therapeutics follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Aug 30
LENZ Therapeutics: Upcoming PDUFA, Strong Data, Some Risks
Summary Graphite Bio reverse merged with Lenz Therapeutics to focus on presbyopia, a $3bn+ market impacting 1.8 billion people globally. LNZ100, a 1.75% Aceclidine eye drop solution, conducted two positive phase 3 clinical trials for presbyopia, showing promising results. LENZ has a market cap of $617mn, cash balance of $226mn, submitted an NDA in August, and has $500mn peak sales estimate. Read the full article on Seeking Alpha주주 수익률
| LENZ | US Pharmaceuticals | US 시장 | |
|---|---|---|---|
| 7D | -24.2% | -3.4% | -1.0% |
| 1Y | -89.1% | 44.7% | 14.1% |
수익률 대 산업: LENZ은 지난 1년 동안 43.7%의 수익을 기록한 US Pharmaceuticals 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: LENZ은 지난 1년 동안 13.1%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| LENZ volatility | |
|---|---|
| LENZ Average Weekly Movement | 9.7% |
| Pharmaceuticals Industry Average Movement | 8.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
안정적인 주가: LENZ는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: LENZ의 주간 변동성(10%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2013 | 152 | Eef Schimmelpennink | www.lenz-tx.com |
는 미국에서 시력 개선 치료제의 개발 및 상용화에 주력하는 상업용 제약 회사로 운영되고 있습니다. 이 회사의 제품 후보로는 성인 노안 치료를 위한 VIZZ와 LNZ101이 있습니다. 렌츠 테라퓨틱스는 이전에 프리즈비피아 테라퓨틱스(Presbyopia Therapies, Inc.)로 알려졌으며 2021년 6월에 렌츠 테라퓨틱스로 사명을 변경했습니다.
LENZ Therapeutics, Inc. 기초 지표 요약
| LENZ 기초 통계 | |
|---|---|
| 시가총액 | US$142.18m |
| 순이익 (TTM) | -US$126.00m |
| 매출 (TTM) | US$21.48m |
6.6x
주가매출비율(P/S)-1.1x
주가수익비율(P/E)LENZ는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| LENZ 손익계산서 (TTM) | |
|---|---|
| 매출 | US$21.48m |
| 매출원가 | US$1.77m |
| 총이익 | US$19.70m |
| 기타 비용 | US$145.70m |
| 순이익 | -US$126.00m |
최근 보고된 실적
Jun 30, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -4.01 |
| 총이익률 | 91.74% |
| 순이익률 | -586.74% |
| 부채/자본 비율 | 0% |
LENZ의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/09/12 02:33 |
| 종가 | 2026/09/11 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
LENZ Therapeutics, Inc.는 10명의 분석가가 다루고 있습니다. 이 중 7명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Yigal Nochomovitz | Citigroup Inc |
| Matthew Caufield | H.C. Wainwright & Co. |